Feliza Mirasol is the science editor for 

Articles

Sara Fathollahi, PhD, product application specialist at DFE Pharma, makes the case of how excipient suppliers can support the transition from batch to continuous manufacturing.

A Look at How Excipient Suppliers Can Support Adoption of Continuous Manufacturing (AAPS PharmSci 360)

Sara Fathollahi, PhD, product application specialist at DFE Pharma, discusses a major challenge in the adoption of continuous manufacturing.

The Challenge of Raw Material Variation in Adopting Continuous Manufacturing (AAPS PharmSci 360)

The guidance describes the agency’s procedures for performing remote interactive evaluations at drug manufacturing and bioresearch monitoring facilities. 

FDA Provides Guidance on Remote Facility Evaluations

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

Pharmaceutical Technology Europe® spoke with Dr. Rainer Schmidt from Galvita AG, an excipient manufacturer based in Switzerland, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Producing Excipients as a Platform Technology with Galvita at CPHI Barcelona

Sara Fathollahi, PhD, product application specialist at DFE Pharma, points out important redesign concepts critical to adapting continuous manufacturing.

Redesign Concepts Critical for Continuous Manufacturing (AAPS PharmSci 360)

A recent AAPS Salary Survey shows a rising trend in compensation for pharmaceutical scientists since 2022. 

Salary Survey for Pharma Scientists Shows Increase of 6.7% Since 2022

PENBRAYA combines components from two meningococcal vaccines, Trumenba and Nimenrix.

FDA Approves Vaccine for Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

The treatment has received Priority Review designation, as well as FDA Breakthrough Therapy designation and Orphan Drug designation.

FDA Approves Novel Therapy for Rare Form of Blood Cancers

As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.

CPHI Barcelona: CMOs Expected to Account for 45% Available Bio Capacity in 2027

The winners of the 2023 CPHI Pharma Awards were announced on October 25 at the CPHI Barcelona event.

News